US immigration order strikes against biotech

Autor: Robert Langer, John M. Maraganore, David P. Schenkein, Neil Warma, Chris Adams, Chip Clark, Mark Levin, William Rastetter, Bruce A Leicher, Nancy A Thornberry, Robert I Blum, Jonathan G Rosin, Kleanthis G Xanthopoulos, Timothy D. Harris, Jeff L Cleland, Robert Forrester, Nancy Simonian, Peter Barrett, Stephen Bloch, William J Rieflin, Brian M Gallagher, Lewis Rusty Williams, Doug Doerfler, Richard Ulevitch, David R. Liu, Andrew Levin, P. Grint, Nick J Simon, Pablo J Cagnoni, Daphne Zohar, Kush M Parmar, Guy Macdonald, Corey M McCann, Stelios Papadopoulos, Michael D Clayman, Diego Miralles, Paula Cobb, John Diekman, Jeremy M Levin, Amir Nashat, Samuel G Waksal, Rachel King, Sandford Sandy Zweifach, Gail J Maderis, Ankit Mahadevia, Heather Franklin, Cary G Pfeffer, Steven K Brauer, Akshay Vaishnaw, Clay B. Siegall, Howard Furst, Jonathan S Leff, William J Rutter, Dennis J. Purcell, Mary T Szela, J C Gutierrez-Ramos, Sean A McCarthy, Elizabeth Lr Donley, Yaron Werber, Doug E Williams, Christoph Westphal, Paul Sekhri, W Eddie Martucci, Jeb Keiper, John E Osborn, Simba Gill, Bassil Dahiyat, Steven H Holtzman, Annalisa Jenkins, Saurabh Saha, Matthew J. During, Camille Samuels, Mara G Aspinall, Chad Robins, Jason P Rhodes, Herve Hoppenot, Jeff Kaplan, Michael A Narachi, Amit Rakhit, Julia C Owens, Steve M Paul, Martin Varsavsky, Mark G. Currie, Rajeev Shah, Rob Perez, H. Stewart Parker, Jeff Stein, Leonard Patrick Gage, Perry Karsen, Joel F Martin, Bob More, Matthew Perry, James G McArthur, Gregory J Flesher, Martin Tolar, Andrew Schwab, James A Geraghty, Eric L Dobmeier, Brook Byers, Vanessa King, Mason W. Freeman, Larry Miller, Marco Taglietti, Jeff Albers, Neil A Exter, Michael W Bonney, Ron Cohen, Nick Leschly, Bruce L Booth, William J Newell, Peter Kolchinsky, Ryan J Watts, Paul Laikind, Andrew G. Myers, Cedric Francois, Stephen T Isaacs, Scott Koenig, Michel Vounatsos, Tuan Ha-Ngoc, Nicholas Galakatos, George P Vlasuk, Isaac Ciechanover, Jeff Kindler, Brian M. Cali, Matthew R Patterson, Kenneth I Moch, Tom Graney, Martin Babler, Jonathan J Fleming, Mark A Goldsmith, Daniel M Bradbury, John Mendlein, Mike Powell, Nessan Bermingham, Eric Elenko, H. Robert Horvitz, Yujiro Steve Hata, Mark Pruzanski, Faheem Hasnain, Henri A. Termeer, Maxine Gowen, Scott M Rocklage, Anne VanLent, Thomas Shenk, Leslie Henshaw, Jeff Jonker, Nina Kjellson, Deborah Dunsire, Zoe Barry, Ron C Renaud, Alex Martin, Uri Lopatin, George Scangos, Jean Kim, Kartik Ramamoorthi, Michael Rosenblatt, Nagesh K Mahanthappa, Harvey F. Lodish, Paul B Bolno, Wendell Wierenga, Atul Pande, Barry Greene, Alan Levy, Adrian Ad Rawcliffe, Wende S Hutton, C Geoffrey McDonough, Vicki L. Sato, Jean-Francois Formela, David V. Goeddel, Bill Haney, Rich Heyman, James E Audia, Ron Cooper, Nina Tandon, Brett Ahrens, Julian Adams, Peter Hecht, John J Lee, Stuart L. Schreiber, Laurence E Reid, Bernat Olle, Paul Hastings, John A. Scarlett, Michael Su, David Grayzel, Ted W Love, Arnold J. Levine, Gerhard Koenig, Thomas E Hughes, Jens W Eckstein, Wendy Nelson, Vikas Goyal

Publikováno v: Nature Biotechnology. 35:204-206

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2d10770c0eb9d17bb770366663a693
https://doi.org/10.1038/nbt.3824

Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient

Autor: John A. Scarlett, Kenneth A. Zib, Aart Jan van der Lely, Robert J. Davis, Joop A. M. J. L. Janssen, Alex F. Muller, Steven W. J. Lamberts

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 86:478-481

We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b36655b6bfe201c142d1b57ff3a46c8
https://doi.org/10.1210/jcem.86.2.7206

Growth Hormone (GH) Receptor Blockade with a PEG-Modified GH (B2036-PEG) Lowers Serum Insulin-Like Growth Factor-I but Does Not Acutely Stimulate Serum GH1

Autor: Christian J. Strasburger, William F. Bennett, Michael O. Thorner, Martin Straume, Martin Bidlingmaier, Kenneth A. Zib, John C. Scarlett, Zida Wu, Suzan S. Pezzoli

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 84:2098-2103

B2036-PEG, a GH receptor (GH-R) antagonist, is an analog of GH that is PEG-modified to prolong its action. Nine mutations alter the binding properties of this molecule, preventing GH-R dimerization and GH action. A potential therapeutic role of B2036

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5eed2d761b9fe0dd6ee987834571aaf6
https://doi.org/10.1210/jcem.84.6.5732

Trattamento a lungo termine dell’acromegalia mediante pegvisomant, un antagonista del recettore dell’ormone della crescita

Autor: G. M. Besser, A. J. van der Lely, D. R. Clemmons, Vivien Herman-Bonert, Christian J. Strasburger, Michael O. Thorner, Shlomo Melmed, Paul M. Stewart, Ariel L. Barkan, Lawrence S. Phillips, K. E. Friend, A. Kilbanski, David M. Cook, Annamaria Colao, S. Hacker, R. K. Hutson, Antonio Ciccarelli, Pamela U. Freda, Kenneth A. Zib, Gudmundur Johannsson, John A. Scarlett, Peter J Trainer, Robert J. Davis, Rosario Pivonello, Stavros Stavrou, Laurence Katznelson, Gaetano Lombardi, Mary Lee Vance

Publikováno v: L'Endocrinologo. 3:250-252

Gli attuali approcci terapeutici nella cura dell’acromegalia comprendono: la chirurgia, la radioterapia e la terapia farmacologica. Il pegvisomant e un nuovo antagonista recettoriale del GH che migliora la sintomatologia e i livelli sierici di IGF-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c49e1d2fe0bd48f72e4081384e183803
https://doi.org/10.1007/bf03344434

Pegvisomant in the treatment of acromegaly

Autor: Craig Parkinson, John A. Scarlett, Peter J Trainer

Publikováno v: Advanced drug delivery reviews. 55(10)

Epidemiological studies have highlighted the need for tight control of growth hormone (GH) and insulin-like growth factor I (IGF-I) in patients with acromegaly. Studies highlighting the events involved in GH receptor signaling have allowed the develo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ff9bf269b8dd6932902f9a2fd114cfe
https://pubmed.ncbi.nlm.nih.gov/14499709